Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-NY108 SPECT Imaging in Prostate Cancer
NCT05815394Phase 1Unknown
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NY108 in prostate cancer (PCa), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoints: Evaluation of tissue distribution of 177Lu-Anti-PSMA mAbs(NY108) at 1 year and Incidence of Treatment-Emergent Adverse Events at 1 year. Status: unknown.
02
Drugs
NY108
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05815394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05815394.